

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-184)

SELPERCATINIB

PRONUNCIATION


sel'' per ka' ti nib

THERAPEUTIC CLAIM

Antineoplastic, treatment of solid tumors

1. Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-
2. 6-(2-hydroxy-2-methylpropoxy)-4-(6-{6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl}pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

STRUCTURAL FORMULA



MOLECULAR FORMULA

C<sub>29</sub>H<sub>31</sub>N<sub>7</sub>O<sub>3</sub>

MOLECULAR WEIGHT

525.6

TRADEMARK

None as yet

SPONSOR

Eli Lilly and Company and its wholly-owned subsidiary Loxo Oncology, Inc.

CODE DESIGNATION

LOXO-292

CAS REGISTRY NUMBER

2152628-33-4

UNII

CEGM9YBNGD

WHO NUMBER

10967

SCS